CIK 0001789972 · Non-accelerated filer<br>Smaller reporting company
Cullinan Therapeutics, Inc.
Sign in to watch- Ticker
- CGEM
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 813879991
- Phone
- 617-410-4650
- Business address
- ONE MAIN STREET, SUITE 1350, CAMBRIDGE, MA, 02142
- Former names
- Cullinan Oncology, Inc., Cullinan Management, Inc., Cullinan Oncology, LLC
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $222,000
- in 2 filings, $222K under 10b5-1 plans
Net −$222,000. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2025-02-19 | Michaelson Jennifer Chief Scientific Officer | Grant or award · Stock Option (Right to Buy) | +100,000 | 100,000 | ||
| 2025-02-19 | Savill Corrine Chief Business Officer | Grant or award | +37,500 | 240,990 | ||
| 2025-02-19 | Savill Corrine Chief Business Officer | Grant or award · Stock Option (Right to Buy) | +75,000 | 75,000 | ||
| 2025-02-19 | SUMER JACQUELYN L Chief Legal Officer | Grant or award | +50,000 | 140,651 | ||
| 2025-02-19 | SUMER JACQUELYN L Chief Legal Officer | Grant or award · Stock Option (Right to Buy) | +100,000 | 100,000 | ||
| 2025-02-19 | AHMED NADIM President and CEO | Grant or award | +180,000 | 443,150 | ||
| 2025-02-19 | AHMED NADIM President and CEO | Grant or award · Stock Option (Right to Buy) | +360,000 | 360,000 | ||
| 2025-02-19 | Jones Jeffrey Alan Chief Medical Officer | Grant or award | +65,000 | 179,059 | ||
| 2025-02-19 | Jones Jeffrey Alan Chief Medical Officer | Grant or award · Stock Option (Right to Buy) | +130,000 | 130,000 | ||
| 2025-02-19 | Fenton Mary Kay Chief Financial Officer | Grant or award | +60,000 | 60,000 | ||
| 2025-02-19 | Fenton Mary Kay Chief Financial Officer | Grant or award · Stock Option (Right to Buy) | +120,000 | 120,000 | ||
| 2025-01-06 | Michaelson Jennifer Chief Scientific Officer | Sale 10b5-1 | −4,000 | $12.51 | $50K | 95,760 |
| 2024-12-24 | AHMED NADIM President and CEO | Sale | −8,400 | $11.87 | $100K | 263,150 |
| 2024-12-18 | Michaelson Jennifer Chief Scientific Officer | Sale | −4,693 | $11.41 | $54K | 99,760 |
| 2024-12-18 | Jones Jeffrey Alan Chief Medical Officer | Sale | −4,632 | $11.41 | $53K | 114,059 |
| 2024-12-18 | SUMER JACQUELYN L Chief Legal Officer | Sale | −3,482 | $11.41 | $40K | 90,651 |
| 2024-12-12 | Michaelson Jennifer Chief Scientific Officer | Sale | −3,489 | $12.52 | $44K | 104,453 |
| 2024-11-05 | Michaelson Jennifer Chief Scientific Officer | Sale 10b5-1 | −8,000 | $15.64 | $125K | 107,942 |
| 2024-09-05 | Michaelson Jennifer Chief Scientific Officer | Sale 10b5-1 | −8,000 | $18.09 | $145K | 115,942 |
| 2024-08-08 | Thistle Mary Director | Grant or award · Stock Option (Right to Buy) | +25,743 | 25,743 |
Page 5 of 23 · 446 trades